From Drug Controller General of India
Zydus Cadila announced that it has received an approval from the Drug Controller General of India (DCGI) to initiate Phase I clinical trials for its Investigational New Drug (IND) ZYBK2, a New Chemical Entity (NCE) intended to treat Rheumatoid Arthritis (RA).Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
